Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome
Phase 3
Completed
- Conditions
- Urinary Tract Diseases
- Registration Number
- NCT00239317
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
The purpose of this study is to determine whether Tamusulosin is effective in the treatment of lower urinary tract syndrome with male patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs).
Exclusion Criteria
- Patients with urination disorder accompanied by apparent organic(benign prostatic hyperplasia: BPH) or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Tamsulosin's efficacy in treating lower urinary tract syndrome in males?
How does Tamsulosin compare to alpha-blockers like Alfuzosin in managing male LUTS symptoms?
Are there specific biomarkers that predict Tamsulosin response in patients with benign prostatic hyperplasia?
What are the long-term adverse event profiles of Tamsulosin versus placebo in male LUTS populations?
What are the current combination therapies involving Tamsulosin for lower urinary tract syndrome treatment?